Pulmonary Arterial Hypertension

February 5th 2025

Gossamer also reported encouraging preclinical data related to the combination of seralutinib and Winrevair.

February 1st 2025

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

January 13th 2025

The move means the pulmonary arterial hypertension drug is now available in the United States, Europe, and the United Kingdom.

December 17th 2024

A pooled analysis of two prior trials suggests patients with a variety of cardiac index scores saw improvement when Winrevair was added to background therapy.